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Background
Indoleamine 2, 3-dioxygenase (IDO) converts tryptophan
in various catabolites and has been shown to induce
immune tolerance in different immune-mediated diseases,
including organ transplantation. One of these tolerogenic
metabolites is anthranilic acid. Tranilast is a clinically
approved, structural and functional analogue of anthranilic
acid that has been recently shown to be effective in murine
models of multiple sclerosis and rheumatoid arthritis. We
examined the effect of tranilast in a rat cardiac allograft
model.
Materials and methods
Lewis 1W rat hearts were grafted in MHC-mismatched
Lewis 1A rats. The receiver is orally treated with
650mg/kg of tranilast daily for 30 days. Total spleno-
cytes and purified spleen cell subtypes sorted by FACS
Aria were transferred to sublethaly irradiated rats by i.v
injection the day before transplantation.
Results
Graft survival in recipients treated with tranilast were sig-
nificantly prolonged (66.3±46.7 days, n=53, p<0,0001)
when compared to control group (8.3±2.3 days, n=6) and
in 45% of recipients (n=53) tranilast induced tolerance
(>100 days survival). Adoptive transfer of total spleno-
cytes from tolerant tranilast-treated rats to naïve rats
resulted in tolerance in all animals (n=5). Moreover, sple-
nocytes from these adoptively transferred tolerant recipi-
ents were again capable of transferring tolerance to all
naïve recipients (n=5). Tolerant splenocytes depleted of
T and B cells (n=6) or depleted of T, B and DCs (n=5)
transferred tolerance. Importantly, depletion of CD161
+
cells from T, B and DCs-depleted splenocytes abrogated
tolerance transfer (9.3 ± 0.6 n=3). To confirm these
results, we adoptively transferred CD161
+TCR
- cells from
tolerant rats which resulted in tolerance (130±91.6 days,
n=5, 3/5 recipients >100 days) whereas CD161
-TCR
- cells
from the same animals did not (12.7±4.6 days, n=3,
p<0,005).
Discussion
This is the first demonstration that tranilast mediates
transplantation tolerance. Tolerance was active and trans-
ferable by CD161+TCR- cells that comprise NK cells
(CD161
high) and myeloid-derived suppressor cells
(CD161
low). Experiments are under way to define which of
these cell populations mediate tranilast-induced tolerance
and by which downstream mechanisms.
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